COFCO Biotechnology Co., Ltd. (SHE:000930)
China
· Delayed Price · Currency is CNY 7.21
-0.33 (-4.38%)
Mar 10, 2026, 2:15 PM CST
COFCO Biotechnology Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | 94.71 | 25.13 | -601.63 | 1,059 | 1,130 | 593.12 | Upgrade
|
| Depreciation & Amortization | 501.96 | 501.96 | 491.84 | 458.19 | 449.81 | 436.4 | Upgrade
|
| Other Amortization | 24.44 | 24.44 | 17.37 | 17.96 | 20.79 | 25.74 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.15 | 0.15 | -1.16 | 145.82 | 203.22 | 13.98 | Upgrade
|
| Asset Writedown & Restructuring Costs | 2.27 | 2.27 | 54.45 | 13.3 | 21.48 | 27.07 | Upgrade
|
| Loss (Gain) From Sale of Investments | -42.25 | -42.25 | 10.33 | 4.08 | -41.92 | 23.54 | Upgrade
|
| Provision & Write-off of Bad Debts | 35.97 | 35.97 | -0.15 | 0.21 | 0.21 | -0.08 | Upgrade
|
| Other Operating Activities | 1,590 | 546.17 | 641.07 | 278.15 | 347.89 | 416.92 | Upgrade
|
| Change in Accounts Receivable | -199.05 | -199.05 | 1,011 | -1,052 | 2,418 | -2,276 | Upgrade
|
| Change in Inventory | -653.64 | -653.64 | 679.83 | 83.07 | 760.34 | -2,462 | Upgrade
|
| Change in Accounts Payable | -42.82 | -42.82 | -287.46 | -329.12 | -414.53 | 270.69 | Upgrade
|
| Change in Other Net Operating Assets | -4.86 | -4.86 | -14.35 | -6.27 | 8.67 | 23.57 | Upgrade
|
| Operating Cash Flow | 1,270 | 155.81 | 1,958 | 708.44 | 4,842 | -2,911 | Upgrade
|
| Operating Cash Flow Growth | 60.54% | -92.04% | 176.38% | -85.37% | - | - | Upgrade
|
| Capital Expenditures | -624.08 | -483.3 | -634.52 | -565.78 | -1,110 | -987.52 | Upgrade
|
| Sale of Property, Plant & Equipment | 1.32 | 16.44 | 166.32 | 246.92 | 270.39 | 102.11 | Upgrade
|
| Divestitures | - | - | - | - | 160.52 | - | Upgrade
|
| Investment in Securities | 102.85 | - | - | 5.6 | - | - | Upgrade
|
| Other Investing Activities | 149.76 | 90.22 | -104.8 | 12.68 | 10.96 | -13.62 | Upgrade
|
| Investing Cash Flow | -370.14 | -376.64 | -572.99 | -300.58 | -667.9 | -899.03 | Upgrade
|
| Long-Term Debt Issued | - | 6,877 | 7,565 | 6,437 | 8,253 | 9,440 | Upgrade
|
| Long-Term Debt Repaid | - | -6,115 | -7,275 | -6,521 | -11,627 | -5,566 | Upgrade
|
| Net Debt Issued (Repaid) | 38.49 | 761.5 | 289.33 | -84.59 | -3,374 | 3,873 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | - | 89.15 | Upgrade
|
| Common Dividends Paid | -89.83 | -93.48 | -1,172 | -554.75 | -277.34 | -164.35 | Upgrade
|
| Other Financing Activities | 25.37 | -156.58 | 2.91 | 45.05 | -50.03 | -43.61 | Upgrade
|
| Financing Cash Flow | -25.97 | 511.45 | -880.04 | -594.28 | -3,702 | 3,755 | Upgrade
|
| Foreign Exchange Rate Adjustments | 12.34 | 27.52 | 11.07 | 40.37 | -4.32 | -0.54 | Upgrade
|
| Net Cash Flow | 885.76 | 318.14 | 516.02 | -146.05 | 467.69 | -55.84 | Upgrade
|
| Free Cash Flow | 645.46 | -327.49 | 1,323 | 142.66 | 3,732 | -3,898 | Upgrade
|
| Free Cash Flow Growth | 92.67% | - | 827.69% | -96.18% | - | - | Upgrade
|
| Free Cash Flow Margin | 3.55% | -1.63% | 6.49% | 0.72% | 15.84% | -19.58% | Upgrade
|
| Free Cash Flow Per Share | 0.35 | -0.18 | 0.72 | 0.08 | 2.02 | -2.10 | Upgrade
|
| Cash Income Tax Paid | 259.19 | 291.39 | 214.77 | 227.63 | 603.27 | 229 | Upgrade
|
| Levered Free Cash Flow | 628.42 | -400.99 | 1,267 | 192.1 | 3,071 | -4,424 | Upgrade
|
| Unlevered Free Cash Flow | 688.91 | -335.45 | 1,337 | 246.55 | 3,170 | -4,365 | Upgrade
|
| Change in Working Capital | -938.03 | -938.03 | 1,346 | -1,268 | 2,711 | -4,448 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.